Venetoclax Plus Azacitidine, Low Dose Cytarabine, Aclarubicin and G-CSF (VA-CAG Regimen) for Newly Diagnosed Young Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, SingleArm Phase 2 Clinical Trial

被引：0

作者：

Li, Xiaoping ^{[1
]}

Li, Xiaoyan ^{[2
]}

Jin, Yanling ^{[3
]}

Chen, Zucong ^{[4
]}

Shen, Yonglin ^{[5
]}

Yuan, Zhongtao ^{[1
]}

Liu, Lin ^{[1
]}

Li, Yu ^{[1
]}

Luo, Le ^{[1
]}

Hou, Shiqian ^{[6
]}

Zhou, Chaoyang ^{[7
]}

Qiu, Chie ^{[8
]}

Zhang, Kui ^{[9
]}

Li, Chunfu ^{[10
,11
]}

Liang, Yang ^{[12
]}

Sanbin, Wang, Sr. ^{[1
]}

机构：

[1] 920th Hosp Joint Logist Support Force, Dept Hematol, Kunming, Yunnan, Peoples R China

[2] First Peoples Hosp Baoshan, Baoshan, Peoples R China

[3] First Peoples Hosp Qujing, Qujing, Peoples R China

[4] Dehong Peoples Hosp, Dehong, Peoples R China

[5] Peoples Hosp Honghe, Honghe, Peoples R China

[6] Peoples Hosp Yuxi, Yuxi, Peoples R China

[7] Peoples Hosp Chuxiong, Chuxiong, Peoples R China

[8] Northeast Cent Hosp Yunnan Prov, Zhaotong, Peoples R China

[9] Second Peoples Hosp Qujing, Qujing, Peoples R China

[10] Nanfang Hosp, Guangzhou, Peoples R China

[11] Nanfang Chunfu Childrens Inst Hematol & Oncol, Dongguan, Peoples R China

[12] Yale Univ, Sch Med, Yale Canc Ctr, Guangzhou, Guangdong, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174469

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial
Huang, Rui
Lin, Xiaonan
Zhang, Yuming
Su, YongZhong
Wang, Caixia
Zhou, Jihao
Huang, Zhenqian
Huang, Jinxiong
Zhang, Xiong
Zhao, Ying
Liang, Yuexiong
Wang, Xiaotao
Gu, Xuekui
He, Honghua
Zheng, Yaling
Tu, Sanfang
Chen, FeiHeng
Lin, Shaoze
Wang, Yaya
Dong, Ying
Huang, Pengcheng
Liu, Zenghui
Xu, Xiaoli
Liang, Zhao
Zhou, Xuan
Li, Meifang
Luo, Man
Wu, Ming
Jiang, Fang
Liu, Qin
Zeng, Hui
Song, Chaoyang
Li, Yuhua
BLOOD, 2023, 142
[22] Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
Becker, Pamela S.
Medeiros, Bruno C.
Appelbaum, Frederick R.
Scott, Bart Lee
Hendrie, Paul C.
Storer, Barry
Pierce, Sherry
Petersdorf, Stephen H.
Estey, Elihu H.
BLOOD, 2011, 118 (21) : 1545 - 1545
[23] Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial
Chen, Suning
Xie, Jundan
Yang, Xiaofei
Shen, Hongjie
Cen, Jiannong
Yao, Li
Hu, Xiaohui
Wu, Qian
Zhang, Jingren
Qiu, Hongchun
Tang, Xiaowen
Sun, Aining
Xue, Shengli
Wang, Ying
Qiu, Huiying
Wu, Depei
BLOOD, 2021, 138
[24] Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
Kadia, Tapan M.
Faderl, Stefan
Ravandi, Farhad
Jabbour, Elias
Garcia-Manero, Guillermo
Borthakur, Gautam
Ferrajoli, Alessandra
Konopleva, Marina
Burger, Jan
Huang, Xuelin
Wang, Xuemei
Pierce, Sherry
Brandt, Mark
Feliu, Jennie
Cortes, Jorge
Kantarjian, Hagop
CANCER, 2015, 121 (14) : 2375 - 2382
[25] The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study
Yang, Li
Liu, Ligen
Zhao, Limin
Lu, Yingting
Zhang, Jing
Sun, Lihua
BLOOD, 2019, 134
[26] Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
Xiaohui Suo
Fang Zheng
Dongmei Wang
Liyun Zhao
Jie Liu
Ling Li
Zhihua Zhang
Congcong Zhang
Yinling Li
Sisi Yang
Xuemei Zhao
Rui Shi
Yan Wu
Zongjiu Jiao
Jiaojie Song
Ling Zhang
Xinxiao Lu
Linyu Yuan
Sifeng Gao
Jilei Zhang
Xingli Zhao
Guanchen Bai
Kaiqi Liu
Yingchang Mi
Experimental Hematology & Oncology, 12
[27] Outpatient Low-Dose Venetoclax Plus Azacitidine Vs. Intensive Chemotherapy for Newly Diagnosed Fit Patients with Acute Myeloid Leukemia in a Limited Resource Setting
Lopez-Garcia, Yadith Karina
De La Garza, Fernando
De la Rosa-Flores, Gerardo Alexis
Coronado Alejandro, Edgar Ulises
Vega-Mateos, Antonio
Tejada Vasquez, Ana Cristina
Garcia-Salas, Gerardo
Garcia-Zarate, Valeria
Colunga-Pedraza, Perla R. Rocio
Gomez-Almaguer, David
Gomez-De Leon, Andres
BLOOD, 2023, 142
[28] Remission Induction With Low Dose Chemotherapy Plus G-CSF in Newly Diagnosed Acute Myeloid Leukemia in the Unidad Nacional de Oncologia Pediatrica (UNOP), Guatemala
Velasquez, T.
Cruz, K.
Alfaro, J.
Blanco, J.
Antillon-Klussmann, F.
Fernandez, K.
Valverde De Gonzalez, P.
Conter, V.
Ribeiro, R. C.
PEDIATRIC BLOOD & CANCER, 2020, 67 : S327 - S327
[29] Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial
Xie, Jundan
Yang, Xiaofei
Bao, Xiebing
Shen, Hongjie
Cen, Jiannong
Yao, Li
Hu, Xiaohui
Wu, Qian
Zhang, Jingren
He, Xuefeng
Tang, Xiaowen
Sun, AiNing
Qiu, Hongchun
Xue, Shengli
Wang, Ying
Fu, Jianhong
Qiu, Huiying
Wu, Depei
Chen, Suning
BLOOD, 2022, 140 : 1439 - 1440
[30] Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms
Raychaudhuri, Suravi
Gooley, Ted
Rasmussen, Allegra
Quach, Kim
Gill, Zach
Halpern, Anna B.
Appelbaum, Jacob S.
Ghiuzeli, Cristina Maria
Hendrie, Paul C.
Cassaday, Ryan D.
Walter, Roland B.
Estey, Elihu
Percival, Mary-Elizabeth M.
BLOOD, 2024, 144 : 4288 - 4289

← 1 2 3 4 5 →